Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BMS-986504 in MTAP-deleted advanced or metastatic non-small cell lung cancer after prior treatment
CTR20254680Phase 2Active
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MRTX1719 in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Sep 2025; status: active.
02
Drugs
MRTX1719
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20254680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254680.